# An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

> **NCT07593391** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Neuren Pharmaceuticals Limited** · enrollment: 180 (estimated)

## Conditions studied

- Phelan-McDermid Syndrome

## Interventions

- **DRUG:** NNZ-2591

## Key facts

- **NCT ID:** NCT07593391
- **Lead sponsor:** Neuren Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-06
- **Primary completion:** 2028-10-29
- **Final completion:** 2028-11-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593391, "An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07593391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*